Program Code: SCF-REMBIO-0001

Classification: Neurophysiology × Sleepomics × Neuroimmune Biology × Circadian Systems Biology

Development Stage: Discovery Biomarker Platform

I. Scientific Objective

To identify, validate, and stratify biomarkers that regulate:

• REM initiation
• REM maintenance
• REM termination
• REM density
• REM emotional processing
• REM memory reconsolidation
• REM neuroimmune interactions
• REM circadian synchronization

using a multi-omic framework integrating:

• Genomics
• Transcriptomics
• Epigenomics
• Proteomics
• Metabolomics
• Connectomics
• Neurophysiology
• Chronobiomics

consistent with SCF reverse-engineering methodology.

II. REM Homeostasis Architecture

Core REM Control Systems

III. SCF REM Regulatory Network

Central REM Axis

REM-On Systems

Primary neuronal populations:

• Sublaterodorsal nucleus (SLD)
• Pedunculopontine nucleus (PPN)
• Laterodorsal tegmental nucleus (LDT)

Major neurotransmitters:

• Acetylcholine
• Glutamate

REM-Off Systems

Primary populations:

• Locus coeruleus
• Dorsal raphe nucleus
• Ventrolateral PAG

Major neurotransmitters:

• Norepinephrine
• Serotonin

REM stability depends on dynamic oscillation between these systems.

IV. Discovery Biomarker Domains

A. Genomic Biomarkers

Circadian Regulation

REM Vulnerability Genes

Discovery Endpoint

REM Susceptibility Polygenic Score (RSPS)

B. Transcriptomic Biomarkers

REM Activation Signature

Upregulated during healthy REM:

Transcript

BDNF

ARC

EGR1

NPAS4

CREB-dependent genes

REM Dysregulation Signature

Transcript

CRH

FOS

JUN

IL6

TNFA

NFKB1

SCF Interpretation

Measures active REM-state biological processing.

C. Epigenomic Biomarkers

DNA Methylation

Candidate loci:

Locus

FKBP5

BDNF

PER3

CLOCK

NR3C1

Histone Modifications

Endpoint

REM Epigenetic Adaptation Index (REAI)

D. Proteomic Biomarkers

REM-Promoting Proteins

REM-Destabilizing Proteins

Protein

CRH

IL-6

TNF-α

HMGB1

Orexin-A (excessive)

Composite Endpoint

REM Stability Protein Panel (RSPP)

E. Metabolomic Biomarkers

Neurotransmitter Metabolites

Energy Metabolism

Marker

NAD+/NADH

ATP

Lactate

Pyruvate

Acetyl-CoA

The SCF framework identifies energy-state disturbances as major fault nodes influencing neural synchronization and behavioral regulation.

F. Neuroimmune Biomarkers

Cytokines

Biomarker

IL-1β

IL-6

TNF-α

IFN-γ

MCP-1

Microglial Activity

Marker

sTREM2

YKL-40

TSPO PET signal

Purpose

Quantify inflammatory influence on REM architecture.

G. Connectomic Biomarkers

REM Functional Connectivity Network

Nodes

• Amygdala
• Hippocampus
• Ventromedial Prefrontal Cortex
• Anterior Cingulate Cortex
• Insula

Primary Biomarkers

Metric

Amygdala-PFC coupling

Hippocampal synchrony

Salience network activity

Default mode network coherence

Limbic integration score

H. Sleepomic Biomarkers

Polysomnographic Measures

Marker

REM latency

REM density

REM duration

REM fragmentation

REM transition probability

REM microarousals

Novel Discovery Endpoints

REM Stability Index (RSI)

RSI = REM duration ÷ REM fragmentation

REM Integrity Score (RIS)

Weighted composite of:

• REM density
• REM continuity
• REM latency
• REM oscillatory coherence

I. Electrophysiologic Biomarkers

EEG

Marker

Theta power

Gamma bursts

PGO-like activity

REM spectral entropy

EOG

Marker

Eye movement density

Saccadic clustering

REM burst amplitude

EMG

Marker

Muscle atonia index

Phasic twitch density

J. Chronobiomic Biomarkers

Circadian Phase Measures

Biomarker

Melatonin onset

Melatonin amplitude

Cortisol rhythm

Core body temperature nadir

Circadian phase angle

REM-Specific Circadian Marker

REM Circadian Synchronization Index (RCSI)

Measures alignment between:

• Melatonin rhythm
• REM onset
• Cortisol suppression

V. REM-Dysregulation Endotype Discovery Framework

Endotype 1 — Hyperadrenergic REM

Biomarkers:

• High MHPG
• High cortisol
• High CRH
• REM fragmentation

Endotype 2 — Neuroimmune REM

Biomarkers:

• IL-6
• TNF-α
• TSPO activation
• Reduced REM continuity

Endotype 3 — Circadian REM Instability

Biomarkers:

• PER3 variants
• Delayed melatonin phase
• Variable REM latency

Endotype 4 — Trauma-Reconsolidation REM

Biomarkers:

• FKBP5
• PACAP signaling
• Amygdala hyperconnectivity

Endotype 5 — Neurodegenerative REM

Biomarkers:

• α-synuclein
• Neurofilament light chain
• Reduced REM atonia
• Brainstem degeneration markers

VI. Translational Biomarker Panel (Priority Tier)

Tier 1 — Clinical Deployment

• REM latency
• REM density
• Cortisol
• Melatonin
• BDNF
• IL-6
• TNF-α

Tier 2 — Precision Stratification

• FKBP5 methylation
• PER3 genotype
• TSPO PET imaging
• Functional connectivity mapping

Tier 3 — Advanced Discovery

• Single-cell transcriptomics
• Extracellular vesicle proteomics
• CSF metabolomics
• Digital REM phenotyping

VII. Proposed SCF REM Biomarker Composite Score

REM Regulatory Integrity Score (RRIS)

Integrated domains:

Output:

• 0–25 Severe REM Dysregulation
• 26–50 Moderate Dysregulation
• 51–75 Stable REM Regulation
• 76–100 Optimal REM Homeostasis

Strategic Next Research Pathways

1. Single-cell atlas of human REM-active neuronal populations.
2. Longitudinal REM multi-omics cohorts across PTSD, depression, narcolepsy, and neurodegeneration.
3. CSF-derived extracellular vesicle biomarker discovery.
4. AI-enabled REM connectomic pattern recognition.
5. Multi-omic REM biomarker validation under FDA biomarker qualification pathways.

MASTER REGISTRY INDEX

SCF-REMBIO-0001 — REM Sleep-Regulation Biomarker Discovery Program

SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol (Universal Template)

SCF-SEF-MD-0001 — SCF Synergistic Evaluation Framework

SCF-SCP-0001 — Synergistic Compatibility Principles

SCF-FDA-REG-0001 — FDA Drug Development & Biomarker Translation Framework